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Nephrogenic systemic fibrosis is a severe disabling disease
that can follow gadolinium-based contrast exposure. In this
study we analyzed the clinical and laboratory records of
patients with nephrogenic systemic fibrosis who had a
history of exposure to gadolinium-based contrast media and
identified their cardiac and vascular events. At autopsy, we
found that the heart, blood vessels, and skin of three patients
who died of cardiac and/or vascular complications had
appreciable amounts of gadolinium, iron, and aluminum as
measured by inductively coupled plasma-mass spectrometry
and confirmed by x-ray fluorescence. Of the 32 patients with
nephrogenic systemic fibrosis studied, 10 died at a median of
112 days after diagnosis. Cardiovascular events contributed
to the mortality of 9 patients and included congestive heart
failure, recurrent arrhythmias, hypotension, stroke, limb
ischemia, posterior ischemic optic neuropathy and sudden
death. Our results show that increased cardiac and vascular
complications along with short survival in nephrogenic
systemic fibrosis are associated with metal accumulation in
the heart, blood vessels, and skin of these patients.
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Nephrogenic systemic fibrosis (NSF) is a systemic illness
comprised of fibrosis1 and systemic inflammation,2,3 and is
reported almost exclusively in patients with renal insuffi-
ciency who are exposed to gadolinium-based contrast
material.4 On the basis of the demonstration of gadolinium
in the skin of NSF patients,5 the USFDA recently issued a
black box warning about the risk of NSF upon gadolinium-
based contrast material exposure. Demonstration of signifi-
cant quantities of insoluble gadolinium in the skin of NSF
patients, months after gadolinium-based contrast material
exposure and after extensive tissue processing, suggests that
gadolinium might have undergone transmetallation in vivo.
Supporting the importance of transmetallation, all NSF cases
reported thus far have been associated with linear magnetic
resonance contrast agents4,6–8 that have inferior thermo-
dynamic stability9,10 and a kinetic or conditional stability that
favors transmetallation.
Only limited data exist on the clinical course and
prognosis in NSF.2,6 Gadolinium-based contrast material
exposure induces pro-inflammatory effects and iron mobi-
lization.6 Iron mobilization, in addition to being an indicator
of transmetallation, may increase the risk of cardiovascular
complications.11–13 To study this hypothesis further, in the
present study we evaluated the clinical history of all NSF
patients who died at a single tertiary-care institution, the
University of Arkansas for Medical Sciences (UAMS). In three
patients for whom an autopsy was obtained, we quantified
metals including gadolinium, iron, and aluminum found in
various organs sampled including the heart as well as the
arteries.
RESULTS
Demographic and clinical data
The median time of follow-up after NSF diagnosis was 226
(2–1050) days. During this period, there were 10 (31.3%)
deaths of the 32 patients followed at UAMS. The median time
between gadolinium exposure and NSF diagnosis was 83.5
(4–555) days. The median time between NSF diagnosis and
death was 112 (37–263) days. The median age at death was 55
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(37–84) years; of those, seven were female. Six patients had
diabetes mellitus prior to the diagnosis of NSF, whereas one
patient subsequently developed new-onset diabetes mellitus.
None of the patients had been treated with aluminum-based
phosphate binders. All patients had been exposed to
gadodiamide at variable doses (15ml to angiographic doses)
and frequency before the development of NSF. Seven patients
had end-stage renal disease at the time of gadolinium
exposure and three patients developed acute worsening of
kidney function and became dialysis dependent after
gadolinium exposure.
Clinical conditions associated with death
Cardiovascular disease contributed to mortality in the
majority of UAMS patients (n¼ 9) and in one patient at the
University of Colorado Health Sciences Center (UCHSC).
Sepsis (n¼ 5) and discontinuation of dialysis (n¼ 1) con-
tributed to mortality in some patients. Cardiac and vascular
causes that contributed to the demise of NSF patients include
congestive heart failure (CHF; n¼ 3), hypotension (n¼ 4),
cardiac arrhythmias (n¼ 2), myocardial ischemia (n¼ 1),
sudden death (n¼ 1), stroke (n¼ 1), and limb ischemia
(n¼ 1). One patient developed blindness secondary to
posterior ischemic optic neuropathy. The patient from
UCHSC also died of CHF and a persistent cardiac arrhythmia
(Table 1). Dialysis was discontinued prior to death in one
patient because of multiple comorbidities related to restricted
mobility, pain, and an ensuing poor quality of life.
Histopathology data and quantification of metals on an
autopsy specimen
A complete autopsy was performed on two NSF patients who
died at UAMS. The first patient developed NSF four days
after gadolinium exposure and died one month later with
new-onset limb ischemia and gangrene, myocardial ischemia,
and hypotension (Figure 1). A histopathologic examination
of tissues sampled at autopsy demonstrated diffuse ulcerative
calcific atherosclerosis, patchy myocardial necrosis and
fibrosis, central venous congestion of the liver, calciphylaxis,
and necrotic skin upon the lower extremity. On quantitative
analysis, significant quantities of gadolinium could be
detected in the skin (411 mg g1), heart (344.4 mg g1), aorta
(48.9 mg g1), kidney (190 mg g1), lungs (81 mg g1), liver
(116 mg g1), and spleen (53 mg g1). Analysis of the heart
revealed 207 mg g1 of iron and analysis of the aorta revealed
354 mg g1 of iron and (51.9 mg g1) aluminum.
In the second patient, NSF was diagnosed two months
after exposure to gadolinium contrast; this patient died nine
months later following sudden onset monocular blindness
(posterior ischemic optic neuropathy), stroke, and hypoten-
sion. A histopathologic examination of tissues sampled at
autopsy revealed diffuse mural calcification of arterial
vasculature including the temporal artery and branches to
multiple viscera, extensive scleral calcification, diffuse
myocardial fibrosis, and central venous congestion of the
liver. On quantitative analysis, significant quantities of
gadolinium could be detected in the skin (255 mg g1), heart
(374 mg g1), aorta (436 mg g1), kidney (395 mg g1), lungs
(368 mg g1), liver (108 mg g1), spleen (277 mg g1), eyes
(83 mg g1), and temporal artery (203 mg g1). An analysis of
the heart revealed increased quantities of iron (62.9 mg g1)
and aluminum (29.9 mg g1). An immunohistochemical stain
of a coronary artery showed proliferation of CD34-positive
spindle cells; the same artery also contained a significant
quantity of gadolinium and iron (Figure 2).
Similarly, in the patient who died of CHF and recurrent
arrhythmia at UCHSC, significant quantities of gadolinium
could be detected in his heart (two sample areas; 442 and
426 mg g1) and soft tissue (skin and underlying muscle of the
right arm; 100.4mg g1). A histopathology of the heart
revealed significant fibrosis (Figure 3).
These data were then compared with data from three
control skin biopsies obtained during re-excision of basal cell
skin cancer and three renal arteries obtained from deceased
potential kidney donors for metal content using inductively
coupled plasma–mass spectrometry (ICP–MS) (Table 2). As
Table 1 | Demographics and clinical conditions that contributed to mortality in NSF patients
Patient
no.
Age
(years) Sex Diabetes Dialysis MRI indication
Dosage/
frequency of
gadolinium Clinical conditions
1 68 M DM Yesa Angiogram 40 Hypotension, dialysis withdrawal
2 37 F DM Yesa Angiogram 60 Staphylococcal sepsis
3 55 M No Yes MRI brain Multiple CHF, sepsis
4 42 F New DM Yes MRI spine Multiple Sudden visual loss and stroke, hypotension
5 55 F DM Yesa MRI brain 20 CHF, respiratory failure, arrhythmia, sepsis
6 63 M DM Yes Angiogram 100 CHF, hypotension
7 84 F No Yes Angiogram 100 Recurrent atrial fibrillation, staphylococcal sepsis
8 47 F No Yes Angiogram Angiographic
dose
Limb ischemia, hypotension, myocardial ischemia,
shock
9 55 F DM Yes MRI leg 20 Sudden death
10 51 F DM Yesa MRI brain Multiple Sudden cardiac death, hypotension, respiratory
failure, sepsis
CHF, congestive heart failure; DM, diabetes mellitus; F, female; M, male; MRI, magnetic resonance imaging; NSF, nephrogenic systemic fibrosis.
aAcute renal failure.
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shown, significantly higher iron accumulation was evident in
the NSF biopsies compared with controls. Although statis-
tically insignificant, aluminum content was also higher in the
NSF skin biopsies and aorta than in controls. The vascular
iron content in the blood vessels of NSF patients was also
higher than the reported iron content (9.4 mg g1) in normal
blood vessels.14
Because prior reports of gadolinium deposition in the
affected tissue of NSF were confined only to the skin and soft
tissue, an independent means to confirm gadolinium
deposition within cardiac tissue was sought. Sections of
fibrotic heart tissue from the UCHSC autopsy case (same
sections identified in Figure 3) were cut using a cleaned
microtome with new blade onto a pure quartz microscopy
slide. This slide was placed in an X-ray fluorescence
microprobe that allowed for detection of gadolinium with a
sensitivity of about o1mg g1.15 The tissue demonstrated a
strong gadolinium emissions spectra (Figure 4), providing
independent verification of gadolinium deposition within the
fibrotic cardiac tissue of this patient with NSF.
DISCUSSION
In this study, we present several novel observations. First, our
data, with a median time to death of just 112 days, indicates
that the onset of NSF may be a harbinger of short survival.
Second, we report several unique cardiac and vascular events
in NSF including sudden monocular blindness secondary to
a
b
Figure 1 |Nephrogenic systemic fibrosis and limb ischemia
after magnetic resonance angiography. New-onset limb
ischemia (a) and nephrogenic systemic fibrosis (b) 1 month after
exposure to gadolinium contrast media in a patient with end-
stage renal disease on peritoneal dialysis. A significant amount of
gadolinium (49mgg1) was detected in the aorta 36 days after
gadolinium-based contrast exposure.
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Figure 2 |Coronary artery disease with vascular gadolinium
deposition. (a) Coronary artery disease in a patient with
nephrogenic systemic fibrosis with CD34-positive cells.
Appreciable quantities of gadolinium were present in the vessel
wall. (b and c) Iron particles demonstrated in the vessel wall using
electron scanning microscopy.
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posterior ischemic optic neuropathy, limb ischemia, and
recurrent cardiac arrythmias. Third, we present the first
evidence that NSF is associated with systemic deposition of
metals including gadolinium, iron, and aluminum, with the
highest quantity of gadolinium deposited in the heart, blood
vessels, and skin.
In a recent study, crude mortality rates were 21.2% for
patients undergoing peritoneal dialysis and 24.4% for
patients undergoing hemodialysis with a mean follow-up of
876 days.16 According to the USRDS data, the mortality risk
for patients on dialysis is 216 per 1000 patient-years.17
Compared to these findings, our study indicates that
mortality is higher (31.3% at 226 days) after an NSF
diagnosis and may also be accelerated (median time to death
of just 112 days). Specifically, accelerated cardiac and vascular
disease was an important cause of death and some NSF
patients died of cardiac and limb ischemia as early as one
month after the onset of gadolinium-associated NSF
(Figure 1). Additionally, these patients suffered unique
vascular events such as posterior ischemic optic neuropathy.
Although the mechanism of these excess and unique cardiac
and vascular events in NSF is unknown, our data suggest that
the accumulation of metals such as gadolinium, iron, and
aluminum might account for these events. In fact, the highest
levels of gadolinium were found in the heart and aorta in two
of our patients with myocardial fibrosis who died with
myocardial ischemia and recurrent cardiac arrythmias.
Possible mechanisms for gadolinium toxicity are currently
under evaluation. One such postulated mechanism, already
reported by us, includes profound iron mobilization,
transferrin oversaturation, and a systemic inflammatory
response as a result of gadolinium exposure.18 Iron is capable
of inducing transmetallation of gadolinium chelates and this
may liberate free gadolinium that is toxic.9 Iron mobilized by
the introduction of gadolinium contrast may also be directly
toxic to the endothelium via oxidative stress (Fenton
reaction).12 Finally, aluminum19–22 and systemic inflamma-
tion12 can aggravate iron-mediated injury. Thus, a combina-
tion of free gadolinium, catalytic iron, aluminum, systemic
inflammation, and oxidative stress may initiate endothelial
injury that evolves into a systemic fibrosing process of the
tissues that is characteristic of NSF. Thus, metal deposition
may contribute to as well as worsen any preexisting
myocardial fibrosis and vascular calcification,23 ventricular
dysfunction, and arrhythmogenicity and high mortality in
NSF. Preexisting vascular disease,3,24 a known risk factor for
NSF, may amplify these risks.
Bone aluminum accumulation is a well-known phenom-
enon in dialysis patients.25 However, to our knowledge,
cutaneous or vascular aluminum accumulation has never
been reported. Possible mechanisms and source of excess
aluminum accumulation in the tissues of NSF patients is
unclear. However, we could speculate several possible
mechanisms. Competition for transferrin binding between
iron and aluminum could be important.26 Unavailability of
Figure 3 |Myocardial fibrosis in a patient with nephrogenic
systemic fibrosis and recurrent cardiac arrythmias.
Appreciable quantities of gadolinium (442mgg1) were present in
the myocardial tissues.
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Figure 4 |X-ray fluorescence microprobe for detection of
gadolinium in the myocardium of an NSF patient with
myocardial fibrosis shown in Figure 3. The tissue demonstrates
strong gadolinium emission spectra.
Table 2 | Quantification of metal deposition in different
organs of NSF patients and controls using ICP–MS
Heart Aorta Skin
Patients Gd Fe Al Gd Fe Al Gd* Fe* Al
Patient 1 344 207 23 49 138 112 411 974 1965
Patient 2 374 63 30 436 833 204 41 2072 1668
Patient 3 442 130 61 — — — 454 618 120
— Arteries Skin
Controls — — — Gd Fe Al Gd Fe Al
Control 1 — — — 0.007 68 14 0.1 107 82
Control 2 — — — 0.006 77 2 0 265 119
Control 3 — — — 0.011 29 3 0.4 202 138
Al, aluminum; Fe, iron; Gd, gadolinium; ICP–MS, inductively coupled plasma–mass
spectrometry; NSF, nephrogenic systemic fibrosis.
All values are presented as mg per g of dry tissue.
Arteries and skin were obtained from different control patients.
*Po0.1 versus controls using Wilcoxon test.
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transferrin-binding sites because of low serum transferrin
levels and saturation of the remaining binding sites by
mobilized iron6 and gadolinium27,28 may result in excess
plasma free aluminum and consequent tissue deposition.
Increased dietary intake in the context of poor urinary
excretion could have contributed additionally to tissue
aluminum load.29 It is feasible that some of the excess tissue
aluminum along with iron participated in the transmetalla-
tion of gadolinium contrast.
Sepsis and discontinuation of dialysis are two additional
factors that contributed to death in NSF-afflicted patients.
Although sepsis is a common cause of death in dialysis
patients,30 gadolinium toxicity and deposition may increase
the risk of sepsis through iron mobilization,31 pro-inflam-
matory/immunomodulatory effects,6 and deposition in the
reticuloendothelial system.32,33 Our discovery of renal
deposition of gadolinium is also an important finding
because acute, irreversible renal failure has been observed
in some patients who develop NSF after exposure to
gadolinium contrast.6 Iron is well-known to play a role in
kidney injury leading to renal tubular toxicity and fibrosis.34
This finding is of significant relevance even in patients with
end-stage renal disease as loss of residual renal function
significantly increases the risk of cardiovascular complica-
tions and death.35
There are several limitations to our study including the
retrospective nature of the observations and limited sample
size. In addition, controls for metal analysis were obtained
from patients who did not have renal insufficiency, were not
exposed to gadolinium, and did not have NSF. Thus, we
cannot rule out tissue accumulation of metals in patients
with renal failure exposed to gadolinium but without NSF. A
systemic evaluation of adjusted annual mortality rates in NSF
patients could not be evaluated by this study because of a
highly variable follow-up and small sample size. We observed
higher tissue metal accumulation and concomitant increased
cardiovascular mortality in NSF. However, our current study
is not designed to address a cause–effect relationship between
these two observations. Additional studies will be required to
address some of these issues.
On the basis of our observations, we conclude that onset
of NSF heralds a high risk of mortality from cardiac and
vascular injury and fibrosis potentially related to systemic
deposition of gadolinium, iron, and aluminum, demons-
trable in various organs but with the highest amount of
gadolinium detected in the heart and blood vessels. We
speculate that metal deposition may potentially determine
the severity of clinical manifestations and outcome of
gadolinium contrast toxicity in patients with renal insuffi-
ciency. Finally, it is conceivable that in some patients
cardiovascular manifestations of NSF may occur with
variable or minimal involvement of other organs such as skin.
MATERIALS AND METHODS
Approval from the Institutional Review Board of UAMS and
appropriate exemption from the Colorado Multiple Institution
Review Board (COMIRB) was obtained. Thirty-four patients with
NSF were identified from UAMS records and additional follow-up
data could not be obtained in two of these patients. Of the
remaining 32 UAMS patients diagnosed with NSF, 10 died and their
data are included for further analysis. Relevant clinical history and
laboratory parameters were recorded and the factors leading to
death were abstracted from their medical records. Cardiovascular
complications such as hypotension, arrhythmias, organ ischemic
syndromes (stroke, myocardial infarction, and limb ischemia),
sudden cardiac death, and CHF after NSF diagnosis were recorded.
Sepsis occurring after an NSF diagnosis was also recorded. The date
of gadolinium exposure, type of gadolinium contrast agent
administered, and estimated renal function at the time of exposure
were examined.
In two NSF patients who died at UAMS, a complete autopsy was
performed after an informed consent was obtained, and the sampled
organs and blood vessels were evaluated for gadolinium, iron, and
aluminum quantity using ICP–MS. Autopsy data on one additional
NSF patient who died at the University of Colorado Health Sciences
Center (UCHSC) were also included.
De-identified paraffin-embedded blocks were submitted to
investigators in Colorado for the purpose of gadolinium quantifica-
tion. Quantitative measurement via ICP–MS on 30 tissue blocks was
performed in a fashion similar to the previously published
techniques of one of the authors (WAH).36 Multiple 30 mM sections
were cut from tissue blocks and then deparaffinized using twice-
distilled xylene and ethanol. Both the autopsy tissues and control
tissue biopsies were subjected to a similar de-paraffinization
procedure. After drying at 105 1C until a constant dry weight was
obtained, samples were placed into quartz tubes and digested with
trace-metal-grade strong acids to fully oxidize all organic material.
Digested samples were analyzed using ICP–MS on a PerkinElmer
6100 DRC Plus instrument (PerkinElmer Life and Analytical
Sciences Inc., Waltham, MA, USA). Total gadolinium (Gd) ions
were monitored at dual masses of 157.924Da for 158Gd and
159.927Da for 160Gd. Other ions monitored included iron (Fe) at
the dual masses of X (54Fe, 53.940Da) and Y (56Fe, 55.935Da), and
aluminum (Al) at the mass of Z (27Al, 26.982Da). Determination of
micrograms of gadolinium and other metals per milligrams of dry
tissue was calculated. Positive and negative control blanks were
included in the analysis to confirm proper functioning of the
equipment.
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